Optimal Level of Financial Regulation under the GATS: A Regulatory Competition and Cooperation Framework for Capital Adequacy and Disclosure of Information
In: Journal of international economic law, Band 5, Heft 2, S. 507-530
ISSN: 1464-3758
4 Ergebnisse
Sortierung:
In: Journal of international economic law, Band 5, Heft 2, S. 507-530
ISSN: 1464-3758
In: 14th Greenhouse Gas Control Technologies Conference Melbourne 21-26 October 2018 (GHGT-14)
SSRN
Working paper
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
BASE
AstraZeneca ; European Union Horizon 2020 research (under grant agreement No 668858 PrECISE to J.S.R.) ; Wellcome Trust (102696 and 206194)
BASE